More than 50% of patients with chronic heart failure present with iron deficiency, which is associated with reduced quality of life and worse prognosis. Intravenous iron supplementation therapy has been shown to improve clinical outcomes in these patients.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Mosterd, A. & Hoes, A. W. Clinical epidemiology of heart failure. Heart 93, 1137–1146 (2007).
Klip, I. T. et al. Iron deficiency in chronic heart failure: an international pooled analysis. Am. Heart J. 165, 575–582.e3 (2013).
Comín-Colet, J. et al. Iron deficiency is a key determinant of health-related quality of life in patients with chronic heart failure regardless of anaemia status. Eur. J. Heart Fail. 15, 1164–1172 (2013).
Anker, S. D. et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N. Engl. J. Med. 361, 2436–2448 (2009).
Ponikowski, P. et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur. Heart J. 36, 657–668 (2015).
Ponikowski, P. et al. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet 396, 1895–1904 (2020).
Hoes, M. F. et al. Iron deficiency impairs contractility of human cardiomyocytes through decreased mitochondrial function. Eur. J. Heart Fail. 20, 910–919 (2018).
Tajes, M. et al. Neurohormonal activation induces intracellular iron deficiency and mitochondrial dysfunction in cardiac cells. Cell Biosci. 11, 89 (2021).
McDonagh, T. et al. Screening, diagnosis and treatment of iron deficiency in chronic heart failure: putting the 2016 European Society of Cardiology heart failure guidelines into clinical practice. Eur. J. Heart Fail. 20, 1664–1672 (2018).
US National Library of Medicine. ClinicalTrials.gov https://www.clinicaltrials.gov/ct2/show/NCT03074591 (2020).
Acknowledgements
We thank the Multidisciplinary Community Heart Failure Unit and the Advanced Heart Failure and Heart Transplantation Unit of Bellvitge University Hospital for their daily work in improving the quality of life and prognosis of patients with HF.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
P.M. and J.C.-C. have received an unrestricted grant from Vifor Pharma for editorial support and open access of previous publications. J.C.-C. has received speaker fees from Vifor Pharma and belonged to the steering committees of the FAIR-HF, CONFIRM-HF and AFFIRM-HF trials.
Rights and permissions
About this article
Cite this article
Moliner, P., Comin-Colet, J. Iron deficiency and supplementation therapy in heart failure. Nat Rev Cardiol 19, 571–572 (2022). https://doi.org/10.1038/s41569-022-00747-0
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41569-022-00747-0
